<code id='36C95A3266'></code><style id='36C95A3266'></style>
    • <acronym id='36C95A3266'></acronym>
      <center id='36C95A3266'><center id='36C95A3266'><tfoot id='36C95A3266'></tfoot></center><abbr id='36C95A3266'><dir id='36C95A3266'><tfoot id='36C95A3266'></tfoot><noframes id='36C95A3266'>

    • <optgroup id='36C95A3266'><strike id='36C95A3266'><sup id='36C95A3266'></sup></strike><code id='36C95A3266'></code></optgroup>
        1. <b id='36C95A3266'><label id='36C95A3266'><select id='36C95A3266'><dt id='36C95A3266'><span id='36C95A3266'></span></dt></select></label></b><u id='36C95A3266'></u>
          <i id='36C95A3266'><strike id='36C95A3266'><tt id='36C95A3266'><pre id='36C95A3266'></pre></tt></strike></i>

          Home / hotspot / focus

          focus


          focus

          author:fashion    Page View:46878

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In